Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and reference conference ID 8333487:
- +1-888-317-6003 for callers in the United States
- +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
|Verona Pharma plc||US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200|
|Victoria Stewart, Director of Investor Relations and Communicationsfirstname.lastname@example.org|
|Argot Partners(US Investor Enquiries)||Tel: +email@example.com|
|Kimberly Minarovich / Michael Barron|
|Optimum Strategic Communications(International Media and European Investor Enquiries)||Tel: +44 (0)203 950 firstname.lastname@example.org|
|Mary Clark / Karl Hard / Elakiya Rangarajah|
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
- ThreeD Capital Inc. Acquires Securities of Bluesky Digital Assets Corp.
- NEW COMMERCE SPLIT Financial Results to May 31, 2021
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesBarron's, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!